Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-α-acetylmethadol: Importance of clinical investigations to validate in vitro drug metabolism studies

Clinical Pharmacokinetics

Volumn 44, Issue 7, 2005, Pages 731-751

  Kharasch, Evan D ^a,b   Whittington, Dale ^a   Hoffer, Christine ^a   Krudys, Kevin ^c   Craig, Keith ^c   Vicini, Paolo ^c   Sheffels, Pam ^a   Lalovic, Bojan ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^c University of Washington   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; DROPERIDOL; LEVACETYLMETHADOL; ONDANSETRON; RIFAMPICIN; TROLEANDOMYCIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DARK ADAPTATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; DRUG URINE LEVEL; ELECTROSPRAY MASS SPECTROMETRY; ENZYME INDUCTION; ENZYME INHIBITION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; MALE; MIOSIS; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ALGORITHMS; ANALGESICS, OPIOID; AREA UNDER CURVE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; METHADYL ACETATE; MIOSIS; MODELS, BIOLOGICAL; RECEPTORS, OPIOID, MU; REPRODUCIBILITY OF RESULTS; RIFAMPIN; TROLEANDOMYCIN;

EID: 22244468389     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200544070-00005     Document Type: Article

References (52)

1. Kreek MJ, Vocci FJ. History and current status of opioid maintenance treatments: blending conference session. J Subst Abuse Treat 2002; 23: 93-105
2. White JM, Danz C, Kneebone J, et al. Relationship between LAAM-methadone preference and treatment outcomes. Drug Alcohol Depend 2002; 66: 295-301
3. Glanz M, Klawansky S, McAullife W, et al. Methadone vs l-α-acetylmethadol (LAAM) in the treatment of opiate addiction: a meta-analysis of the randomized, controlled trials. Am J Addict 1997; 6: 339-49
4. Johnson RE, Chutuape MA, Strain EC, et al. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000; 343: 1290-7
5. Clark N, Lintzeris N, Gijsbers A, et al. LAAM maintenance vs methadone maintenance for heroin dependence (Cochrane Review). Cochrane Database Syst Rev 2002; (2): CD002210
6. Sorensen JL, Copeland AL. Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend 2000; 59: 17-31
7. Rawson RA, Hasson AL, Huber AM, et al. A 3-year progress report on the implementation of LAAM in the United States. Addiction 1998; 93: 533-40
8. Deamer RL, Wilson DR, Clark DS, et al. Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM). J Addict Dis 2001; 20: 7-14
9. Jones HE, Strain EC, Bigelow GE, et al. Induction with levomethadyl acetate: safety and efficacy. Arch Gen Psychiatry 1998; 55: 729-36
10. Eissenberg T, Stitzer ML, Bigelow GE, et al. Relative potency of levo-a-acetylmethadol and methadone in humans under acute dosing conditions. J Pharmacol Exp Ther 1999; 289: 936-45
11. Kaiko RF, Inturrisi CE. Disposition of acetylmethadol in relation to pharmacologic action. Clin Pharmacol Ther 1975; 18: 96-103
12. Henderson GL, Wilson BK, Lau DHM. Plasma l-α-acetylmethadol (LAAM) after acute and chronic administration. Clin Pharmacol Ther 1976; 21: 16-25
13. Walsh SL, Johnson RE, Cone EJ, et al. Intravenous and oral l-α-acetylmethadol: pharmacodynamics and pharmacokinetics in humans. J Pharmacol Exp Ther 1998; 285: 71-82
14. Nickander R, Booher R, Miles H. α-l-Acetylmethadol and its N-demethylated metabolites have potent opiate action in the guinea pig isolated ileum. Life Sci 1974; 14: 2011-7
15. Horng JS, Smits SE, Wong DT. The binding of the optical isomers of methadone, α-methadol, α-acetylmethadol and their N-demethylated derivatives to the opiate receptors of rat brain. Res Commun Chem Pathol Pharmacol 1976; 14: 621-9
16. Walczak SA, Makman MH, Gardner EL. Acetylmethadol metabolites influence opiate receptors and adenylate cyclase in amygdala. Eur J Pharmacol 1981; 72: 343-9
17. Vaupel DB, Jasinski DR. l-α-Acetylmethadol, l-α-acetyl-N- normethadol and l-α-acetyl-N,N-dinormethadol: comparisons with morphine and methadone in suppression of the opioid withdrawal syndrome in the dog. J Pharmacol Exp Ther 1997; 283: 833-42
18. Holtzman SG. Discriminative stimulus properties of levo-α- acetylmethadol and its metabolites. Pharmacol Biochem Behav 1979; 10: 565-8
19. Finkle BS, Jennison TA, Chinn DM, et al. Plasma and urine disposition of l-α-acetylmethadol and its principal metabolites in man. J Anal Toxicol 1982; 6: 100-5
20. 3H]acetylmethadol (LAAM) in acutely and chronically treated monkeys. J Pharmacol Exp Ther 1978; 206: 475-91
21. Moody DE, Alburges ME, Parker RJ, et al. The involvement of cytochrome P450 3A4 in the N-demethylation of L-α-acetylmethadol (LAAM), norLAAM, and methadone. Drug Metab Dispos 1997; 25: 1347-53
22. Oda Y, Kharasch ED. Metabolism of levo-α-acetylmethadol (LAAM) by human liver cytochrome P450: involvement of CYP3A4 characterized by atypical kinetics with two binding sites. J Pharmacol Exp Ther 2001; 297: 410-22
23. Huang W, Bemis PA, Slawson MH, et al. Determination of l-α-acetylmethadol (LAAM), norLAAM, and dinorLAAM in clinical and in vitro samples using liquid chromatography with electrospray ionization and tandem mass spectrometry. Pharm Sci 2003; 92: 10-20
24. Neff JA, Moody DE. Differential N-demethylation of l-α- acetylmethadol (LAAM) and norLAAM by cytochrome P450s 2B6, 2C18, and 3A4. Biochem Biophys Res Commun 2001; 284: 751-6
25. Oda Y, Kharasch ED. Metabolism of methadone and levo-α- acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation. J Pharmacol Exp Ther 2001; 298: 1021-32
26. Kharasch ED, Russell M, Mautz D, et al. The role of cytochrome P450 3A4 in alfentanil clearance: implications for interindividual variability in disposition and perioperative drug interactions. Anesthesiology 1997; 87: 36-50
27. Billings RE, McMahon RE. L-acetylmethadol (LAM) treatment of opiate dependence: plasma and urine levels of two pharmacologically active metabolites. Life Sci 1974; 14: 1437-46
28. Phimmasone S, Kharasch ED. A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. Clin Pharmacol Ther 2001; 70: 505-17
29. Kharasch ED, Jubert C, Senn T, et al. Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. J Clin Pharmacol 1999; 39: 664-9
30. Kharasch ED, Russell M, Garton K, et al. Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe. Anesthesiology 1997; 87: 26-35
31. Barrett PH, Bell BM, Cobelli C, et al. SAAM II: simulation, analysis, and modeling software for tracer and pharmacokinetic studies. Metabolism 1998; 47: 484-92
32. Houston JB. Drug metabolite kinetics. Pharmacol Ther 1982; 15: 521-52
33. St Pierre MV, Xu X, Pang KS. Primary, secondary, and tertiary metabolite kinetics. J Pharmacokinet Biopharm 1988; 16: 493-527
34. Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res 1972; 5: 411-59
35. Schuetz EG, Schuetz JD, Strom SC, et al. Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocytes. Hepatology 1993; 18: 1254-62
36. Madan A, Graham RA, Carroll KM, et al. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 2003; 31: 421-31
37. Ono S, Hatanaka T, Hotta H, et al. Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 1996; 26: 681-93
38. Sai Y, Dai R, Yang TJ, et al. Assessment of specificity of eight chemical inhibitors using cDNA- expressed cytochromes P450. Xenobiotica 2000; 30: 327-43
39. Ibrahim AE, Feldman J, Karim A, et al. Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. Anesthesiology 2003; 98: 853-61
40. Kharasch ED, Hoffer C, Whittington D, et al. Role of hepatic and intestinal cytochrome CYP3A and CYP2B6 in the metabolism, disposition and miotic effects of methadone. Clin Pharmacol Ther 2004; 76: 250-69
41. Kharasch ED, Walker A, Hoffer C, et al. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass CYP3A activity: noninvasive assessment using pupillary miosis. Clin Pharmacol Ther 2004; 76: 452-66
42. McCance-Katz EF, Rainey PM, Smith P, et al. Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and nelfinavir. Am J Addict 2004; 13: 163-80
43. Moody DE, Walsh SL, Rollins DE, et al. Ketoconazole, a cytochrome P450 3A4 inhibitor, markedly increases concentrations of levo-acetyl-α-methadol in opioid-naive individuals. Clin Pharmacol Ther 2004; 76: 154-66
44. Huang L, Wring SA, Woolley JL, et al. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab Dispos 2001; 29: 754-60
45. Zhu W, Song L, Zhang H, et al. Dexamethasone differentially regulates expression of carboxylesterase genes in humans and rats. Drug Metab Dispos 2000; 28: 186-91
46. Ebling WF, Szefler SJ, Jusko WJ. Analysis of cortisol, methylprednisolone, and methylprednisolone hemisuccinate: absence of effects of troleandomycin on ester hydrolysis. J Chromatogr B 1984; 305: 271-80
47. Roerig DL, Hasegawa AT, Wang RIH. Effect of alteration of metabolism on the analgesic activity, toxicity, distribution and excretion of l-α-acetylmethadol in the rat. J Pharmacol Exp Ther 1977; 203: 377-87
48. Kuttab SH, Nowshad F, Shargel L. Effect of phenobarbital pretreatment on the plasma and urinary levels of (-)-α-acetylmethadol and its metabolites. J Pharm Sci 1985; 74: 331-4
49. Kovac AL. Prevention and treatment of postoperative nausea and vomiting. Drugs 2000; 59: 213-43
50. Dixon CM, Colthup PV, Serabjit-Singh CJ, et al. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 1995; 23: 1225-30
51. Dershwitz M, DiBiase PM, Rosow CE, et al. Ondansetron does not affect alfentanil-induced ventilatory depression or sedation. Anesthesiology 1992; 77: 447-52
52. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003; 31: 815-32